Zobrazeno 1 - 10
of 33
pro vyhledávání: '"F U, Dzgoeva"'
Autor:
N. G. Malakhova, F. U. Dzgoeva, O. V. Remizov, V. H. Botsieva, Z. R. Ikoeva, V. G. Goloeva, E. Yu. Gireyeva, L. V. Tsallagova, A. E. Gurina
Publikováno v:
Nephrology (Saint-Petersburg). 26:72-79
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f3024f8f663f64b9d5a3b83a4eb50d5
https://doi.org/10.36485/1561-6274-2022-26-3-72-79
https://doi.org/10.36485/1561-6274-2022-26-3-72-79
Publikováno v:
Терапевтический архив, Vol 88, Iss 12, Pp 51-56 (2016)
Aim. To determine the nature of changes in fibroblast growth factor 23 (FGF-23) and other bone mineral metabolism parameters detectable in the blood of patients with end-stage chronic renal failure (CRF) and to analyze their links to the development
Externí odkaz:
https://doaj.org/article/3c2bac6090c843f6894b944b4b5d6c9f
Autor:
V. G. Goloeva, F. U. Dzgoeva, Z. R. Ikoeva, L. V. Tsallagova, A. E. Gurina, E. Yu. Gireyeva, V. Kh. Botsieva, N. G. Malakhova, O. V. Remizov
Publikováno v:
Nephrology (Saint-Petersburg). 25:63-70
BACKGROUND. Cardiovascular complications caused by vascular calcification in chronic kidney disease (CKD) are closely related to disorders of bone and mineral metabolism, the mechanisms of which require further study.THE AIM: to clarify the role of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca9845def4e70ae2c47abbee0fb3cdca
https://doi.org/10.36485/1561-6274-2021-25-6-63-70
https://doi.org/10.36485/1561-6274-2021-25-6-63-70
Publikováno v:
Терапевтический архив, Vol 87, Iss 6, Pp 68-74 (2015)
Aim. To establish possible pathogenetic relationships between the marker of bone mineral metabolism fibroblast growth factor 23 (FGF-23) and the markers of cardiovascular diseases characterizing the state of cardiomyocytes and that of the vascular wa
Externí odkaz:
https://doaj.org/article/bffa14f3f3d145a68fbf98a5f48d3e52
Publikováno v:
Терапевтический архив, Vol 86, Iss 6, Pp 63-69 (2014)
AIM: To study the role of the bone mineral metabolic mediators osteoprotegerin (OPG) and fibroblast growth factor 23 (FGF-23) in the mechanisms of cardiovascular events (CVEs) in chronic kidney disease (CKD)/MATERIAL AND METHODS: Sixty-eight patients
Externí odkaz:
https://doaj.org/article/240894b93d9c420a87ec07a15ddf27d1
Autor:
F U Dzgoeva, T M Gatagonova, Z K Kadzaeva, O V Khamitsaeva, Z Kh Kochisova, A T Dzutseva, B G Bazaeva, T L Bestaeva
Publikováno v:
Терапевтический архив, Vol 85, Iss 6, Pp 44-50 (2013)
AIM: To study the specific features of diastolic dysfunction (DD) in different types of left ventricular (LV) hypertrophy (LVH) in patients with end-stage renal failure (ESRF) and to estimate the cardioprotective effect of erythropoietin/MATERIAL AND
Externí odkaz:
https://doaj.org/article/4b773c08497f4a86985f7b2eb4f9d5d9
Publikováno v:
Nephrology (Saint-Petersburg). 24:18-28
In chronic kidney disease (CKD), progressive decline in kidney function leads to disorders of mineral metabolism, which are usually called secondary hyperparathyroidism. An increase in the serum concentration of the parathyroid hormone is associate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bc56a101a326a5f85a065acaffed9d7
https://doi.org/10.36485/1561-6274-2020-24-5-18-28
https://doi.org/10.36485/1561-6274-2020-24-5-18-28
Autor:
Fatima Uruzmagovna Dzgoeva, Tamara Magametovna Gatagonova, Zarina Kazbekovna Kadzaeva, Ol'ga Vasil'evna Khamitsaeva, Zalina Khasanovna Kochisova, Argentina Taymurazovna Dzutseva, Bela Georgievna Bazaeva, F U Dzgoeva, T M Gatagonova, Z K Kadzaeva, O V Khamitsaeva, Z Kh Kochisova, A T Dzutseva, B G Bazaeva
Publikováno v:
Терапевтический архив, Vol 83, Iss 6, Pp 42-46 (2011)
Aim. To ascertain mechanisms of development of left ventricular hypertrophy (LVH) and possible cardioprotective action of anemia correction in patients with end-stage renal disease. Material and methods. A total of 98 patients (53 females and 45 male
Externí odkaz:
https://doaj.org/article/5d5fd709129c4fc198f8a17be5da403e
Publikováno v:
Nephrology (Saint-Petersburg). 23:78-83
Thrombotic microangiopathies (TMAs) are induced by several underlying conditions; most are resolved by treating background disease. Eculizumab is a human monoclonal antibody that blocks the final stage of the complement system and effectively treats
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f630a5e171056d3a6e8e1cb0377a91d
https://doi.org/10.24884/1561-6274-2019-23-3-78-83
https://doi.org/10.24884/1561-6274-2019-23-3-78-83
Autor:
F. U. Dzgoeva, O. V. Remizov
Publikováno v:
Nephrology (Saint-Petersburg). 23:10-20
The Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (European Society of Urogenital Radiology (ESUR)) updated its 2011 guidelines for the prevention of post-contrast acute kidney injury (PC-AKI). The recommendat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c129d1b43974e980f492a5aec8aafae
https://doi.org/10.24884/1561-6274-2019-23-3-10-20
https://doi.org/10.24884/1561-6274-2019-23-3-10-20